Page 11234..10..»

Category Archives: Myocardial Infarction

Myocardial Infarction: Causes, risk factors, symptoms …

Posted: December 19, 2019 at 2:41 pm

The heart is the most vital organ of the body that pumps blood to every other organ. Any aberration in the normal functioning of the heart can lead to serious pathological conditions which might permanently impact the functioning of other organs. At present, heart attack or myocardial infarction has become a critical global health issue Continue reading

Posted in Myocardial Infarction | Comments Off on Myocardial Infarction: Causes, risk factors, symptoms …

Association of Prevalence of Active Transport to Work and Incidence of Myocardial Infarction: A Nationwide Ecological Study – DocWire News

Posted: at 2:41 pm

Abstract BACKGROUND: There is a paucity of population-based geospatial data about the association between active transport andmyocardial infarction. We investigated the association between active transport to work and incidence ofmyocardial infarction. Continue reading

Posted in Myocardial Infarction | Comments Off on Association of Prevalence of Active Transport to Work and Incidence of Myocardial Infarction: A Nationwide Ecological Study – DocWire News

Mandrola’s Top 10 Cardiology Stories of 2019 – Medscape

Posted: at 2:41 pm

1. The ISCHEMIA Trial The ISCHEMIA trial transcends the cath lab and influences much of cardiology practice. Its findings also reach into human psychology. Continue reading

Posted in Myocardial Infarction | Comments Off on Mandrola’s Top 10 Cardiology Stories of 2019 – Medscape

No Causal Effects of Plasma Homocysteine Levels on the Risk of Coronary Heart Disease or Acute Myocardial Infarction: A Mendelian Randomization Study…

Posted: at 2:41 pm

BACKGROUND: Although many observational studies have shown an association between plasma homocysteine levels and cardiovascular diseases, controversy remains. Continue reading

Posted in Myocardial Infarction | Comments Off on No Causal Effects of Plasma Homocysteine Levels on the Risk of Coronary Heart Disease or Acute Myocardial Infarction: A Mendelian Randomization Study…

Icosapent Ethyl Approved to Reduce Risk for CV Events in High-Risk Patients – Endocrinology Advisor

Posted: at 2:41 pm

The Food and Drug Administration (FDA) has approved the use of Vascepa (icosapent ethyl; Amarin Pharma) as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (150mg/dL) and established CV disease or diabetes mellitus and 2 or more additional risk factors for CV disease. The approval was based on data from the phase 3 REDUCE-IT trial that assessed the CV outcomes of 8179 patients who were administered Vascepa as an add-on to statins, and who had elevated TG levels (135mg/dL) with either CV disease or diabetes and other CV risk factors. The primary composite end point included time to first occurrence of CV death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina (5-point major adverse cardiovascular event [MACE]) Continue reading

Posted in Myocardial Infarction | Comments Off on Icosapent Ethyl Approved to Reduce Risk for CV Events in High-Risk Patients – Endocrinology Advisor

Myocardial Infarction Treatment Market to Witness Comprehensive Growth By 2024 – Industry News Ledger

Posted: at 2:41 pm

A leading research firm, Zion Market Research added a latest industry report on "Global Myocardial Infarction Treatment Market" consisting of 110+ pages during the forecast period and Myocardial Infarction Treatment Market report offers a comprehensive research updates and information related to market growth, demand, opportunities in the global Myocardial Infarction Treatment Market. According to the report the Myocardial Infarction Treatment Market to Witness Comprehensive Growth By 2024 The Myocardial Infarction Treatment Market report provides in-depth analysis and insights into developments impacting businesses and enterprises on global and regional level. The report covers the global Myocardial Infarction Treatment Market performance in terms of revenue contribution from various segments and includes a detailed analysis of key trends, drivers, restraints, and opportunities influencing revenue growth of the global consumer electronics market.This report studies the global Myocardial Infarction Treatment Market size, industry status and forecast, competition landscape and growth opportunity Continue reading

Posted in Myocardial Infarction | Comments Off on Myocardial Infarction Treatment Market to Witness Comprehensive Growth By 2024 – Industry News Ledger

Survival Benefit of Coronary Revascularization after Myocardial Perfusion SPECT: The Role of Ischemia – DocWire News

Posted: at 2:41 pm

BACKGROUND: Survival benefit of revascularization over medical therapy (MT) in patients with stable ischemic heart disease (SIHD) is uncertain. We evaluated the prognostic effects of revascularization in patients with SIHD undergoing single-photon emission computed tomographymyocardialperfusion imaging (SPECT-MPI) Continue reading

Posted in Myocardial Infarction | Comments Off on Survival Benefit of Coronary Revascularization after Myocardial Perfusion SPECT: The Role of Ischemia – DocWire News

Vascepa Approved to Cut Risk of CV Events in High-Risk Patients With Elevated Triglycerides – Monthly Prescribing Reference

Posted: at 2:41 pm

The Food and Drug Administration (FDA) has approved the use of Vascepa (icosapent ethyl; Amarin Pharma) as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (150mg/dL) and established CV disease or diabetes mellitus and 2 or more additional risk factors for CV disease. The approval was based on data from the phase 3 REDUCE-IT trial that assessed the CV outcomes of 8179 patients who were administered Vascepa as an add-on to statins, and who had elevated TG levels (135mg/dL) with either CV disease or diabetes and other CV risk factors. The primary composite end point included time to first occurrence of CV death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina (5-point major adverse cardiovascular event [MACE]) Continue reading

Posted in Myocardial Infarction | Comments Off on Vascepa Approved to Cut Risk of CV Events in High-Risk Patients With Elevated Triglycerides – Monthly Prescribing Reference

Cardiometabolic disease costs associated with suboptimal diet in the United States: A cost analysis based on a microsimulation model. – DocWire News

Posted: at 2:41 pm

This article was originally published here Cardiometabolic disease costs associated with suboptimal diet in the United States: A cost analysis based on a microsimulation model. PLoS Med. Continue reading

Posted in Myocardial Infarction | Comments Off on Cardiometabolic disease costs associated with suboptimal diet in the United States: A cost analysis based on a microsimulation model. – DocWire News

Biden is a healthy, vigorous, 77-year-old, according to his doctor – POLITICO

Posted: at 2:41 pm

Questions about age and health have dogged Biden on the campaign trail. He is one of four candidates in their 70s; another is Bernie Sanders, who recently suffered a heart attack Continue reading

Posted in Myocardial Infarction | Comments Off on Biden is a healthy, vigorous, 77-year-old, according to his doctor – POLITICO

Page 11234..10..»